ClinicalTrials.gg
RecruitingNCT06184503LAMPO(0-3)Updated May 16, 2025

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3

An observational study in Alpha-Mannosidosis, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 2 sites in United States. Open to participants aged Up to 3 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
5
Ages
Up to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. alpha-Mannosidosis · Chiesi Farmaceutici S.p.A..

Started
2025
the only one that year
Observational
2 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2025, is one of 2 observational ones, and was the 12th registered.

alpha-Mannosidosis

24 studies on the registry are indexed under alpha-Mannosidosis; 6 are open to participants now.

Browse alpha-Mannosidosis studies →

Open to participants now

1 of the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 5 alpha-Mannosidosis studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: Up to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The goal of this observational study is to learn the effects of the drug velmanase alfa (Lamzede®) in the bodies of children under the age of 3 with Alpha-Mannosidosis.

The main questions it aims to answer are:

  • study the effect of velmanase alfa on a marker of the disease called GlcNAc(Man)2 after one year of therapy
  • explore how the child's body reacts to velmanase alfa during the therapy The parents or legal guardians of participants will be asked to provide the results of analyses performed in the routine clinical setting related to the participant's general health and the administration of velmanase alfa.

Additional data will be extracted from other observational sponsored studies/registries, compassionate use programs, investigator-initiated studies (IIS), and published case reports (presented in the literature) if existing.

03

Conditions studied

  • Alpha-Mannosidosis

Browse trials for

04

Who can participate

Ages eligible
Up to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Paediatric patients with a confirmed diagnosis of alpha mannosidosis via MAN2B1 genetic testing and/or alpha-mannosidase activity in leukocytes or fibroblasts \< 10% of normal activity, with data for at least one pre- and one post-Lamzede treatment sample obtained when \< 3 YOA, after at least 6 weeks of treatment (primary analyses).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with the provision of from their legal guardians (LAR)
  • Have a confirmed diagnosis of alpha mannosidosis
  • Have initiated treatment with velmanase alfa between birth to at least six weeks before turning 3 years of age
  • Have information on the disease marker GlcNAc(Man)2 obtained:

before velmanase treatment initiation (ideally max 6 month before), and at least one post-treatment sample, collected following at least six weeks of treatment.

  • Participants treated with Lamzede, 1 mg/kg body weight, via weekly intravenous infusions.

Exclusion criteria

Exclusion Criteria:

Participants who have undergone prior hematopoietic stem cell transplantation () or other therapies for treating alfa mannosidosis (supportive treatments acceptable).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
5 participants (estimated)
Patient registry
No

Groups and cohorts

  • Paediatric patients with alpha-mannosidosis treated with Lamzede before 3 years of age

    Paediatric patients with a confirmed diagnosis of alpha-mannosidosis with data for at least one pre- and one post-Lamzede treatment sample obtained when \< 3 YOA.

    Drug: Velmanase Alfa

Interventions

  • Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.

    Also known as: Lamzede

06

What researchers measure

Primary outcomes

  1. Pharmacodynamic Response to velmanase alfa

    Change (absolute and relative) of GlcNAc(Man)2 level from pre-velmanase alfa treatment baseline in blood

    Time frame: 52 weeks of treatment

Other outcomes

  1. Development of anti drug antibody to velmanase alfa

    Assessment of the impact of anti drug antibody on pharmacodinamic

    Time frame: 52 weeks of treatment

  2. Treatment-emergent adverse events

    Number of undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment

    Time frame: 52 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Sep 2029, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Dec 28, 2023
StartActual
Feb 19, 2025
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06184503
Responsible party
Sponsor
First posted
Dec 28, 2023
Start date
Feb 19, 2025
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
May 16, 2025

Study contacts

Chiesi Clinical trials
Contact
clinicaltrials_info@chiesi.com
+39.0521 2791

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion